Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Tizona Therapeutics, Inc
Essen Biotech
Novartis
University of Pittsburgh
DEKA Biosciences
Inhibrx Biosciences, Inc
Second Affiliated Hospital of Guangzhou Medical University
Celldex Therapeutics
Kineta Inc.
Cambridge University Hospitals NHS Foundation Trust